Neurofibromatosis 1
Showing 1 - 25 of >10,000
Mitochondrial Dysfunction in Neurofibromatosis Type 1
Not yet recruiting
- Neurofibromatosis 1
- Blood draw
- FACIT-F and Pain Scales
- (no location specified)
Jun 12, 2023
Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)
Not yet recruiting
- Neurofibromatosis 1
- Deoxycholic Acid
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine
Nov 13, 2023
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
(PRO) Measures for Individuals With Neurofibromatosis 1 and
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma, Plexiform
- Medication Event Monitoring System (MEMS)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Development to Predict Malignant Conversion in Neurofibromatosis
Recruiting
- Neurofibromatosis 1
- +2 more
- Whole Body Magnetic Resonance Imaging
-
Baltimore, MarylandJohns Hopkins University
Dec 22, 2022
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Completed
- Neurofibromatosis Type 1
- Neurofibroma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Natural History Study of Patients With Neurofibromatosis Type 2
Recruiting
- Neurofibromatosis
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Neurofibromatosis 1 Trial in Baltimore, Redwood City
Recruiting
- Neurofibromatosis 1
-
Baltimore, California
- +1 more
Aug 17, 2022
Cutaneous Neurofibromas in People With NF1
Recruiting
- Neurofibromatosis Type 1
- +3 more
- Evaluation of the natural history of cutaneous neurofibromas
-
Baltimore, MarylandJohns Hopkins University
Oct 12, 2022
Stressors in Parents of Cancer or Neurofibromatosis Type 1 (NF1)
Completed
- Parents of Children With Cancer
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Cutaneous Neurofibroma Trial in Boston (Kybella, 980nm laser, 755nm Alexandrite Laser)
Recruiting
- Cutaneous Neurofibroma
- Kybella
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine, Massachusetts General Hospital
Aug 10, 2022
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
Neurofibromatosis 1 Trial (curcumin, high phenolic extra virgin olive oil (HP-EVOO))
Recruiting
- Neurofibromatosis 1
- curcumin, high phenolic extra virgin olive oil (HP-EVOO)
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Aug 23, 2022
Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
-
Shanghai, Shanghai, ChinaShanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Malignant Peripheral Nerve Sheath Tumor Development in
Active, not recruiting
- Neurofibromatosis 1
- Peripheral Nerve Neoplasms, Malignant
-
Bethesda, MarylandNational Cancer Institute (NCI)
Jul 6, 2022
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)
Active, not recruiting
- Neurofibromatosis 1
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Neurofibromatosis Type 1 Trial in Los Angeles (Whole-body Magnetic Resonance Imaging)
Recruiting
- Neurofibromatosis Type 1
- Whole-body Magnetic Resonance Imaging
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Jul 11, 2022